Research

Hormonal

Combining multiple receptor pathways (e.g., GLP-1/GIP, GLP-1/Amylin, or GLP-1/Glucagon) produces synergistic and superior weight loss compared to monotherapy, representing a historical inflection point in obesity pharmacotherapy.

Obesity is a chronic biological disease requiring physiological treatment, not just willpower. Modern combination therapies (targeting GLP-1, GIP, Amylin, or Glucagon receptors) are significantly more effective than older drugs or lifestyle changes alone, achieving 15-24% weight loss in trials. While access and cost are current barriers, these medications are designed to be used alongside lifestyle modifications to overcome biological forces promoting weight gain. Consult a provider about whether combination receptor agonists are appropriate for your health profile.

GoodSupportsHIGH confidence
Since neuro-enteroendocrine pathways are redundant and coordinated, targeting more than one of these signals results in more potent and synergistic effects on weight loss outcomes.
Christine Park et al. · Frontiers in Endocrinology · 2025

Why this rating

The paper reviews multiple Phase 2 and 3 trials with human data, though it is a narrative review rather than a single primary RCT.

Source

A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways

Christine Park et al. · Frontiers in Endocrinology · 2025

DOI 10.3389/fendo.2025.1630199

narrative_reviewCited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →